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ABSTRACT
EFFECT OF IN VIVO POLYBROMINATED DIPHENYL ETHER (PBDE) TREATMENT
ON HEPATIC GLYCERONEOGENESIS AND LIPID METABOLISM

by
Kylie R. Cowens
University of New Hampshire, May 2015
Polybrominated diphenyl ethers (PBDEs) are flame-retardant chemicals that
contaminate the environment. Through ingestion and inhalation, these chemicals get
into the human body, where they affect the liver by suppressing the metabolic enzyme
phosphoenolpyruvate carboxykinase (PEPCK), which is partially responsible for
glyceride-glycerol production via glyceroneogenesis. This study investigated the effects
of PBDE-induced hepatic PEPCK suppression on glyceroneogenesis, and the
associated perturbations in liver lipid metabolism. Twenty-eight male, weanling Wistar
rats were treated daily with 14 mg/kg body weight PBDE mixture, DE-71 (TRT, n=14) or
corn oil vehicle (CON, n=14) for 28 days. After a 48-hour fast, rats were sacrificed and
blood and livers removed for analysis of serum metabolites, PEPCK protein levels,
PEPCK activity, liver lipids, and glyceroneogenesis. TRT animals exhibited significant
increases in serum ketones (27%), accompanied by significant decreases in serum
triglycerides (27%), and liver PEPCK protein (23%), PEPCK Vmax (40%), lipids (29%),
and glyceroneogenesis (41%) compared to CON. These findings demonstrate that
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PBDE-induced PEPCK suppression impacts liver lipid metabolism, likely by suppressing
glyceroneogenesis.
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CHAPTER 1

LITERATURE REVIEW

POLYBROMINATED DIPHENYL ETHERS

Background
Polybrominated diphenyl ethers (PBDEs) are a class of brominated
environmental chemicals that were incorporated into consumer products beginning in
the 1970s to decrease flammability of home and office supplies such as electronics,
furniture, and upholsteries (Watkins et al., 2011, Besis and Samara et al., 2012).
Structurally, PBDEs are similar to thyroid hormone, with two phenyl rings connected by
an ether bridge and the potential addition of 2-10 bromines in 209 possible
combinations or congeners (see Figure 1).
Commercially, 3 main classes of PBDEs have been produced: deca-, penta-, and
octa-BDE formulations. These nomenclatures refer to the degree of bromination within
each class: deca-BDE compounds are a mixture of congeners that are nona- or decabrominated; octa-BDE consist of mainly congeners that are hexa-, hepta, or octabrominated; penta-BDE are made mostly from congeners that are tetra- or pentabrominated (McDonald, 2002).
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The phasing out of commercially added penta- and octa- formulations began in
the early 2000’s, followed by the complete phase out of the deca- formulations by the
end of 2013. There are currently no PBDEs in commercial use, but because PBDEcontaining products exist in homes and offices (Costa et al., 2008), PBDEs continue to
persist in the environment.

Figure 1 – Structure of PBDE: two phenyl rings connected by an ether bridge. Bromines
can be added in any combination in the 10 positions indicated, with a minimum of 2
bromines and a maximum of 10. There are 209 possible combinations, or congeners.

PBDEs as environmental contaminants
PBDEs are not chemically bound to the products in which they are used, allowing
for their easy transition into the environment by leaching into soil and groundwater upon
disposal of PBDE-containing products in landfills. Furthermore, PBDEs contaminate the
outdoor air during production and through incineration of disposed products (Osako et
al., 2004, Hale et al., 2008). Once in groundwater, PBDEs are able to penetrate the food
supply, affecting produce and more notably fish and game (Costa et al., 2008). Diet is
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one route of exposure, although more recently indoor inhalation and ingestion of dust
have been identified as significant contributors to human exposure (Costa et al., 2008).
Studies conducted over the past 10 years have indicated that in the US, PBDEs
are present in sediment, sludge, and soil in addition to key dietary sources including
marine animals, dairy products, and meat (Costa et al., 2008). Studies have found
PBDEs to be relevant in the indoor environment as well, with significant levels settling in
dust (Jones-Otazo et al., 2005, Wilford et al., 2005, Wu et al., 2007). PBDEs have been
detected in tissues such as breast milk (Dunn et al., 2010), adipose tissue (JohnsonRestrepo et al., 2005), liver (Covaci et al., 2007), and serum (Sjodjin et al., 2004), with
the greatest burden reported in adipose tissue and liver (Frederiksen et al., 2009). This
illustrates a clear migration of PBDEs from the environment into the human body.

PBDEs in the body
PBDEs are highly lipophilic compounds, and as such, accumulate in adipose
tissue (Johnson-Restrepo et al., 2005). Metabolism however, occurs most notably in the
liver, which participates in oxidative hydroxylation and reductive debromination of parent
PBDE compounds (Stapleton et al., 2009). Both hydroxylated and debrominated
metabolites have been identified in human serum (Athanasiadou et al., 2008, Thuresson
et al., 2006), although the distinct pathways responsible for PBDE degradation remain
unclear (Stapleton et al., 2009). Studies have found hydroxylated metabolites to have
similar in vivo effects as their parent PBDEs (Feo et al., 2013), or in some cases more
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harmful effects (Canton et al., 2005), suggesting in vivo metabolism of PBDEs is a
worthy concern.

Endocrine-disrupting effects
One well-studied consequence of in vivo PBDE exposure is perturbed thyroid
hormone signaling. Due to the similarities in structure between PBDEs and thyroxine, an
inactive form of thyroid hormone, studies have found that PBDEs competitively bind,
and therefore antagonize thyroid receptors α and β (Meerts et al., 2000). Furthermore,
PBDEs have an affinity for binding both transthyretin and thyroxine binding globulin, two
transporters responsible for binding thyroid hormone in circulation (Marchesini et al.,
2008, Hamers et al., 2006).
It has been shown in both rats and mice that triiodothyronine, the active
circulating form of thyroid hormone, is affected by the presence of PBDEs. One study
treated Sprague-Dawley rats daily for 30 days with 100, 300, or 600 mg/kg/day of BDE209, the PBDE congener that is most abundant in human tissue samples (Lee et al.,
2010). Results illustrated a significant decrease in serum triiodothyronine at all three
doses used. This was accompanied by a decrease in serum TSH at 300 and 600
mg/kg/day (Lee et al., 2010). These results are supported by work conducted in a
mouse model, in which male offspring of dams treated with 0, 10, 500, or 1500
mg/kg/day BDE-209 daily for 17 days illustrated a significant decrease in serum
triiodothyronine at both 10 and 1500 mg/kg/day doses (Tseng et al., 2008).
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Taken together, these data suggest exposure to PBDEs affects thyroid
metabolism at several stages, including transport, binding, and hormone availability.
Furthermore, thyroid hormone is a driver of metabolism, and disruption of transport and
signaling of this key hormone raises concern of PBDE-induced metabolic perturbations.

Liver-specific effects
One organ that is a main target for chronic exposure of PBDEs is the liver (Costa
and Giordana, 2007). Considering the role the liver plays in PBDE catabolism, most
notably through oxidative hydroxylation (Stapleton et al., 2009), this organ is likely to
suffer PBDE-associated consequences. The liver is in control of many crucial metabolic
processes and perturbations in function could have both liver-specific, and systemic
consequences.
Although there are limited studies to date focusing on enzymatic or metabolic
consequences of PBDE exposure in the liver, several studies have illustrated hepaticassociated consequences that highlight the liver as an organ of concern. One key
consequence of PBDE exposure is hepatic oxidative stress. Albina et al. (2010) treated
adult male Sprague-Dawley rats with a single dose of 0, 0.6, or 1.2 mg/kg BDE-99, an
environmentally relevant congener. Forty-five days after treatment, animals were
euthanized and livers were analyzed for markers of oxidative stress. Key antioxidant
enzymes including superoxide dismutase (SOD) and catalase (CAT) were found to be
significantly upregulated in livers of treated animals, SOD at both treatment doses and
CAT at the highest dose. Furthermore, the ratio of oxidized to reduced glutathione was

	
  

5	
  

significantly increased, suggesting greater levels of reactive oxygen species associated
with BDE-99 treatment compared to controls.
These data are further supported by work from An and colleagues (2011) in a
study analyzing two PBDE metabolites, 6-hydroxylated and 6-methoxylated BDE-47,
and their effects on a human hepatoma cell line, HepG2. An et al., found that DNA
damage was caused by both of these metabolites in a dose-dependent manner,
accompanied by an increase in SOD activity and a decrease in reduced glutathione.
This suggests that both PBDEs and their metabolites increase hepatic oxidative stress.
Other hepatic perturbations include increases in overall liver weight and fat
accumulation in response to PBDE exposure. Lee et al. (2010) found liver weight was
significantly increased in rats treated with 600 mg/kg/day BDE-209 for 30 days
compared to control animals. Furthermore, these animals exhibited fatty degeneration in
histological analyses of the livers. This is supported by a study conducted by Bruchajzer
et al. (2010) where administration of 200 mg/kg/day of PentaBDE for 14 days resulted in
increased fatty deposition in the livers of female rats, accompanied by an increase in
relative liver mass. Nash et al. (2013) also found an increase in overall liver weight and
relative liver weight in male rats in response to 28 days of treatment with 14 mg/kg DE71, a Penta-BDE mixture. This was accompanied by a significant increase in liver lipid
percentage.
There has been little research on the effects of PBDEs on hepatic lipid or
carbohydrate metabolism. In a recent study, Nash and colleagues (2013) found that
after 28 days of daily treatment with 14 mg/kg DE-71, hepatic phosphoenolpyruvate
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carboxykinase (PEPCK) activity was suppressed by 43%. PEPCK lies at the crossroads
of hepatic carbohydrate and lipid metabolism, and disruptions in hepatic PEPCK activity
could have significant metabolic consequences. Currently, metabolic consequences of
PEPCK disruption by PBDEs are unknown.

PHOSPHOENOLPYRUVATE CARBOXYKINASE

Background
PEPCK is responsible for the decarboxylation and subsequent phosphorylation
of oxaloacetate (OAA) to form phosphoenolpyruvate (PEP), using guanosine
triphosphate (GTP) or inosine triphosphate (ITP) as an energy source, and yielding
GDP or IDP, and CO2 as byproducts (Hanson and Patel, 1994). The main product of
the PEPCK reaction, PEP, is an intermediate metabolite of gluconeogenesis, and is
essential for the de novo production of glucose in times of fasting (Hanson and Patel,
1994, Chakravarty et al., 2005, Yang et al., 2009). PEP is also an intermediate
metabolite of glyceroneogenesis, and is necessary for the de novo formation of glycerol3-phosphate, the backbone of triglyceride (Chakravarty et al., 2005, Yang et al., 2009).
The production of glycerol-3-phosphate, via glyceroneogenesis, is necessary for hepatic
reesterification of fatty acids during times of fasting, when systemic and hepatic fatty
acid levels rise due to increased rates of lipolysis (Chakravarty et al., 2005). Thus,
PEPCK is the first rate-limiting enzyme in both gluconeogenesis and
glyceroneogenesis, responding to changes in diet and hormones, such as glucagon and
glucocorticoids (Chakravarty et al., 2005, Yang et al., 2009). PEPCK is present in two
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forms, a cytosolic (PEPCK-c), and a mitochondrial (PEPCK-m) form, and relative
expression of the two forms is species-dependent. In humans, the relative expression is
50:50, PEPCK-c:PEPCK-m, while in rodents there is a much greater expression of
PEPCK-c, accounting for approximately 90% of the total PEPCK (Hanson and Patel,
1994).

Metabolic roles

Gluconeogenesis
Gluconeogenesis allows for conversion of non-carbohydrate substrates to
glucose by the liver in times of acute fasting, or by the kidney in times of long-term
starvation (Hanson and Patel, 1994). Ablation of whole body PEPCK-c in mouse models
caused significant reductions in blood glucose and the animals did not survive past 3
days of life, illustrating the importance of PEPCK-c’s gluconeogenic function (Hakimi et
al., 2005). Furthermore, whole body PEPCK-c deletion resulted in hepatic fat
accumulation that was 2 to 3 times greater than controls, accompanied by elevated
circulating ketones (Hakimi et al., 2005). These data suggest perturbed lipid metabolism
as well.
Elimination of liver PEPCK-c in mouse models resulted in slight systemic
hyperglycemia, in addition to reduced gluconeogenesis within the liver tissue (She et al.,
2000, Hakimi et al., 2005). The resulting hyperglycemia is likely due to the ability of the
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kidney to perform gluconeogenesis and thereby compensate for losses in liver
gluconeogenic function.
These data illustrate that (1) liver-specific reductions in PEPCK-c reduce
gluconeogenesis, (2) a reduction in hepatic PEPCK-c can be compensated for by renal
PEPCK, and (3) a loss of whole body PEPCK-c perturbs hepatic triglyceride
metabolism, as evidenced by fat accumulation in the liver and increased circulating
ketones.

Glyceroneogenesis
The main role of glyceroneogenesis is the production of glycerol-3-phosphate,
the activated form of glycerol used for esterification of fatty acids to form triglycerides
(Chakravarty et al., 2005, Yang et al., 2009). This occurs largely in the liver, and to a
smaller extent in the adipose tissue (Chakravarty et al., 2005, Yang et al., 2009).
Studies focused on the origin of glycerol-3-phoshpate have demonstrated through
deuterium-labeled water techniques that after an overnight fast, up to 65% of
triglycerides synthesized in the liver and exported in VLDL contain a glycerol backbone
produced via hepatic glyceroneogenesis (Kalhan et al., 2001, Kalhan et al., 2008),
highlighting the importance of this pathway in regulating lipid homeostasis.
Reduced hepatic glyceroneogenesis, a proposed consequence of decreased
hepatic PEPCK, should theoretically decrease available glycerol-3-phosphate, reducing
the amount of fatty acid esterification in the liver and causing a build-up of hepatic fatty
acids. This would enlarge the pool of available fatty acid substrate for ketone synthesis,
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and subsequently increase circulating ketones, a known metabolic consequence of
decreased PEPCK (Hakimi et al., 2005, Stark et al., 2014). In addition, it is expected
that hepatic triglyceride formation would decrease and result in decreased serum
triglycerides. Indeed, reduced serum triglycerides are associated with ablation of hepatic
and renal PEPCK-m (Stark et al., 2014), but fat accumulation in the liver in response to
a loss of PEPCK-c (Hakimi et al., 2005) is contrary to reduced glyceroneogenesis, and
requires further investigation.
Unlike gluconeogenesis, a reduction in hepatic glyceroneogenesis cannot be
compensated for by another tissue. Although there is significant PEPCK activity in white
and brown adipose tissue, the lungs, the jejunum, and the acinar cells of the mammary
gland, in addition to the liver and kidney (Hanson and Patel, 1994), none of these
tissues compensate for losses in hepatic glyceroneogenesis. Adipose tissue has
sufficient PEPCK to participate in glyceroneogenesis, however the enzyme is
differentially regulated in this tissue. While hepatic PEPCK is upregulated in response to
fasting conditions and rising glucagon, adipose tissue PEPCK is suppressed during
fasting, allowing for an increase in fatty acid release. Instead, adipose tissue PEPCK is
upregulated in response to insulin when fatty acids are being made in the liver, and thus
fatty acids can be esterified and stored in adipose, adding another layer of control over
circulating fatty acid levels (Chakravarty et al., 2005), which are linked to diabetes and
cardiovascular disease. Because of this lack of compensation, a PBDE-induced
decrease in hepatic PEPCK may have a greater effect on whole body triglyceride
metabolism, compared to carbohydrate metabolism.
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There is no available data on how PBDE or other environmental chemicals may
affect liver glyceroneogenesis, although there is relevant data from adipose. Recent
work found that decreased PEPCK-c protein in adipose tissue caused by leptin was
accompanied by decreased rates of glyceroneogenesis (Jaubert et al., 2012),
highlighting the link between PEPCK-c suppression and the physiological consequence
of depressed glyceroneogenesis. Due to the high rates of glyceroneogenesis present in
the liver compared to the adipose tissue, combined with the suppression of hepatic
PEPCK by PBDE, disrupted glyceroneogenesis is a likely, but currently unsupported,
metabolic consequence of PBDE exposure.

METABOLIC AND HEALTH CONSEQUENCES OF DEPRESSED
GLYCERONEOGENESIS

Metabolic consequences
There are three possible serum markers of decreased hepatic
glyceroneogenesis: elevated fatty acids, elevated ketones, and suppressed
triglycerides. Because hepatic glyceroneogenesis is largely responsible for esterification
of fatty acids synthesized de novo by the liver (Kalhan et al., 2001, Kalhan et al., 2008),
a decrease in glycerol-3-phosphate could lead to elevated hepatic fatty acids, which
could be released into the blood stream, or act as a substrate for ketone synthesis in the
liver. Although glyceroneogenesis has not been evaluated specifically, studies
evaluating the effects of decreased PEPCK-c and decreased PEPCK-m have
demonstrated an increase in serum ketones, most notably beta-hydroxybutyrate (Hakimi
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et al., 2005, Stark et al., 2014). Increases in fatty acids and ketones would theoretically
be accompanied by suppressed hepatic triglyceride formation, subsequently decreasing
hepatic triglyceride output. Studies have reported variable changes in serum
triglycerides in response to losses in PEPCK-c vs. PEPCK-m function (Hakimi et al.,
2005, Stark et al., 2014), and the role of glyceroneogenesis in relation to these changes
has yet to be addressed.

Health consequences

Insulin Resistance
It has been fairly well established that increases in circulating fatty acid levels are
associated with the development of insulin resistance (Boden, 1991, Boden, 1997,
Boden, 2006). After infusing human subjects with triglycerides and heparin to increase
plasma free fatty acids, Boden used a euglycemic-hyperinsulinemic clamp to
demonstrate that increased fatty acids significantly decreased glucose uptake in the
presence of excess insulin, suggesting the development of acute insulin resistance that
was both dose-dependent and reversible (Boden, 1997). Further work using
euglycemic-hyperinsulinemic clamps supported this development of insulin resistance
by demonstrating that a 35% decrease in glucose infusion rate was required to sustain
euglycemia in rats treated with lipid/heparin and excess insulin (Griffin et al., 1999).
Griffin found evidence to suggest fatty acid disruptions in insulin signaling may be
occurring, and reported that elevated fatty acids affect 3 key steps involved in insulinstimulated glucose uptake in muscle: (1) membrane-association of protein kinase C Θ,
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(2) insulin receptor substrate-1 tyrosine phosphorylation, and (3) PI3-kinase activity.
These decreases were accompanied by a 25% reduction in glucose transport in vivo
(1999). Current research is focused on further elucidation of the mechanisms involved in
fatty acid-induced insulin resistance, expanding on the work done by Griffin and
colleagues (Capurso and Capurso, 2012). An unanswered question is: what are the
mechanisms by which circulating free fatty acids may be increasing, and are metabolic
disruptions of glyceroneogenesis contributing to this increase?

Vascular Disease
Elevation of ketone bodies is implicated in the development of vascular disease,
a complication that is often associated with type 1 and type 2 diabetes (Rains and Jain,
2014). Although current review of the literature suggests that a mild elevation in
circulating beta-hydroxybutyrate (BHB) may be cardioprotective (Dedkova and Blatter,
2014), recent studies have found that more marked increases in circulating ketone
bodies, including BHB and acetoacetate (AA) may contribute to increased oxidative
stress in endothelial tissue, potentially contributing to vascular disease (Rains and Jain,
2014, Kanikarla-Marie and Jain, 2015). A recent study using primary human umbilical
vein endothelial cells demonstrated that treatment with BHB and AA caused a
significant increase in reactive oxygen species (ROS). The addition of glucose to the
media increased ROS to a greater extent (Kanikarla-Marie and Jain, 2015), suggesting
that the presence of elevated ketones in combination with elevated glucose may have
the most detrimental effect. This suggests that hyperglycemia due to diabetes could
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further compound the oxidative stress accompanied by increased circulating ketones.
Taken together, these data imply that the potential consequences of suppressed
glyceroneogenesis, including increased fatty acids and increased ketones, could cause
perturbations that work in concert to disrupt insulin sensitivity and vascular health.

SUMMARY
PBDE are environmental chemicals that are present in the human body and have
known effects on the liver. Chronic PBDE exposure has been shown to suppress
hepatic PEPCK activity, a key enzyme involved in both carbohydrate and lipid
metabolism in the liver. While the kidney can compensate for losses in PEPCK-driven
glucose metabolism, there are no documented tissues or pathways that can
compensate for losses in PEPCK-driven lipid metabolism, including glyceroneogenesis.

HYPOTHESIS
PBDE-induced suppression of PEPCK activity decreases hepatic
glyceroneogenesis and perturbs lipid metabolism.

	
  

14	
  

CHAPTER 2

METHODS

ANIMALS

Experimental model and basic design
The male Wistar rat model was used for all experiments. A total of 28 rats were
received from Charles River Laboratory (Wilmington, MA) weighing 75 to 100 g. After
arrival, animals were given 5 to 8 days to acclimate to their environment. They were
housed in hanging wire cages under a 12 hr light/dark cycle at 70°F and 30 to 70%
relative humidity. Rats were provided standard rat chow and water ad libitum for the
duration of each experiment.
Two experiments were conducted, noted as experiment 1 (n=16), and experiment
2 (n=12). In experiment 1, rats were treated daily for 28 days with 14 mg/kg body weight
DE-71, a commercial PBDE mixture, to assess changes in the liver indicative of
suppressed PEPCK and associated metabolic stress. These data served to inform
experiment 2, in which rats were treated with the same amount of DE-71 for the same
duration to address changes in glyceroneogenesis, hepatic lipid metabolism, and
PEPCK protein.
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After acclimatization, treatment was administered daily between 8:00-10:00 AM,
using a standard gavage method. Animals in the treatment group (TRT) were gavaged
with 14 mg/kg DE-71, while animals in the control group (CON) were gavaged with a
comparable amount of corn oil vehicle. Although treatment starts dates were staggered
so that 4 animals, 2 TRT and 2 CON, could be euthanized per day, each rat was treated
for 28 days, fasted for days 27 and 28, and euthanized on the morning of day 29.

Tissue procurement
Animals were euthanized via CO2 asphyxiation. Immediately post euthanasia,
animals were laid on their dorsal surface, the abdomen was wiped with ethanol, and an
incision was made at the base of the abdomen and extended out and along the sides of
the animal. For experiment 1, upon opening of the body cavity, the diaphragm was cut
allowing access to the heart, where ~5mL of blood was removed via cardiac puncture
using a 5cc syringe attached to an 18-gauge, 1.5” needle. Livers were then removed,
rinsed in cold water, weighed, and whole liver weight was recorded. Two-5mg samples
of liver were removed and fixed in 10% formalin for later histological analysis. The rest
of the liver was divided into approximate 2-gram portions, frozen in liquid nitrogen and
stored at -20°C for later use.
For experiment 2, livers were removed, rinsed, weighed and three-200mg
portions of each liver were removed as follows: the liver was placed on its ventral
surface and the first sample was taken from the outer portion of the far left lobe
(denoted “1” on figure 2). The liver was then turned over (as seen in figure 2), and the
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next sample was taken from the central portion of the far left lobe (denoted “2” on figure
2). The final portion was taken from the tip of the triangular looking lobe (denoted “3” on
figure 2). Liver sections were set on ice for subsequent glyceroneogenesis assay.

3	
  

2	
  

1	
  

Figure 2. Ventral surface of rat liver. Location of samples removed from each liver for
glyceroneogenesis quantification are indicated by respective numbers. (Picture from
Ruehl-Fehlert et al., 2003).
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The rest of the liver was divided into approximate 2-gram portions and
immediately frozen in liquid nitrogen for later determination of PEPCK protein, PEPCK
activity, and liver lipid accumulation.

Preparation of gavage solutions
For experiment 1, a 2-gram aliquot of DE-71 was obtained in an amber glass
bottle from NIEHS (Lot# 1500K07A), originally obtained from Great Lakes Chemical
Corporation. The bottle was stored at room temperature in a dark drawer until solution
preparation. First, 1200 uL hexane was added to the amber glass bottle and stirred with
a glass stir rod for approximately 10 minutes, until the sticky, viscous material was
completely dissolved from the bottom, sides, and mouth of the bottle. The solution was
then poured into a 150mL amber glass bottle containing 60mL corn oil. An additional
51mL corn oil was added to the bottle, which was then vortexed for 60 seconds. The
hexane used to dissolve the DE-71 into solution was evaporated under nitrogen for
approximately 6 hours. The final concentration of DE-71 was 2000mg/111mL, or
18mg/mL, however analysis of previous DE-71 solutions prepared following the same
instructions found DE-71 concentration to be approximately 14mg/mL, suggesting that
some DE-71 may be lost in preparation.
For experiment 2, DE-71 was obtained in a clear glass bottle wrapped in paper
towel and tape from the University of Indiana (Lot# G550QF65A), originally obtained
from Great Lakes Chemical Corporation. To obtain an approximate 2-gram portion, a
small amber glass bottle and stir rod were placed on an analytical scale, which was then
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zeroed. The stir rod was then used to remove a portion of the DE-71 from the clear
glass bottle and transfer it to the amber glass bottle on the scale. A 1.8-gram portion
was obtained, 1080uL hexane was added to the amber glass bottle, and the stir bar
used to transfer the DE-71 from the original source was then used to stir the solution for
approximately 10 minutes, until the DE-71 was entirely dissolved from the bottom and
sides of the amber glass bottle, as well as the bottom and sides of the glass stir rod.
The solution was then transferred to a 150mL amber glass bottle containing 54mL corn
oil. Another 45.9mL corn oil was added to the bottle, which was then vortexed for 60
seconds. The hexane was evaporated under nitrogen for approximately 6 hours. The
concentration of the solution was expected to be similar to those previously prepared by
this method, 14mg/mL.
To prepare the corn oil control solution, the same preparation was used as
above, excluding the addition of DE-71. For experiment 1, 1200uL hexane was added to
111mL corn oil, vortexed for 60 seconds, and hexane was evaporated. For experiment
2, 1080uL hexane was added to 99.9mL corn oil, vortexed for 60 seconds, and hexane
was evaporated.

MEASUREMENTS

Serum metabolites
To analyze biochemical makers of metabolic stress that may accompany PBDE
exposure, serum concentrations of a suite of metabolites were determined from rats in
experiment 1. Blood was collected via cardiac puncture, transferred to 5mL serum
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separator Vacuette® tubes, and left to clot at room temperature for approximately 2
hours before centrifugation at room temperature for 15 minutes at 1200 x g (3000 rpm)
in an IEC – Centra8R centrifuge, to separate serum from plasma. Serum was then
poured off into a plastic, 5mL storage tube and frozen at -20°C. Samples were sent to
Marshfield Laboratories (Marshfield, WI) for determination of the following metabolites:
serum glucose, alanine aminotransferase, alkaline phosphatase, total bilirubin,
cholesterol, total protein, albumin, urea, creatinine, calcium, sodium, potassium,
chloride, globulin, albumin/globulin ratio, urea/creatinine ratio, sodium/potassium ratio,
beta hydroxybutyrate, triglycerides, and non-esterified fatty acids.

Histological analysis
To analyze visual changes in the liver that accompany PBDE exposure and may
be indicative of metabolic stress, histological examination of livers from rats in
experiment 1 was conducted. The formalin-fixed sections of each liver were sent to Dr.
Roger Wells of the New Hampshire Veterinary Diagnostic Lab at the University of New
Hampshire. Dr. Wells cut thin sections from each sample and mounted them on a glass
slide, which he then stained with hematoxylin and eosin. He then evaluated the slides
using light microscopy, providing a histopathology narrative that described the changes
in liver lipid content in the TRT animals compared to CON.
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PEPCK activity
To confirm findings of Nash et al. (2013) that PBDE treatment at 14mg/kg BW for
28 days suppresses hepatic PEPCK activity, frozen liver tissue was used to measure
PEPCK activity using a spectrophotometric method within 3 months of euthanasia in
experiment 2.

Liver cytosol extraction
Four samples were processed at a time. Two CON and two TRT samples were
removed from the freezer and thawed on ice for 30-45 minutes, during which time
homogenization buffer was made fresh. Once thawed, one sample at a time was
weighed, hand minced with scissors, and transferred to a 50mL conical bottom screw
cap tube with 9 volumes of homogenization buffer, followed by homogenization for 15
seconds with a Powerstat® polytron electric homogenizer set at 60.
Samples were centrifuged for 15 minutes at 3116.425 x g (5000 rpm) and 4°C in
a Sorvall Evolution RC centrifuge. Supernatants were removed and centrifuged for 60
minutes at 59466 x g (30,000 rpm) and 4°C in a Beckman L8-80 ultracentrifuge. Glass
Pasteur pipettes were used to remove the fat that had accumulated at the surface of
samples, and the supernatants were transferred with plastic transfer pipettes to 15mL
conical bottom screw cap tubes and placed on ice for immediate spectrophotometric
analysis.
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Spectrophotometric assay
Four prepared samples were kept on ice while being analyzed for PEPCK
activity, one at a time. Liver cytosol containing PEPCK was combined with malate
dehydrogenase (MDH), varying concentrations of malate, and NAD+. MDH uses malate
and NAD+ to produce oxaloacetate (OAA), the substrate for PEPCK, in addition to
NADH, a biochemical that can be measured spectrophotometrically at 340nm. MDH is a
reversible enzyme that will reach equilibrium based on the amount of substrate
available. If PEPCK activity is low and OAA is not being used, MDH will slow down its
production or move the reaction in the opposite direction. NADH is made in a 1:1 ratio
with OAA, so as the production of OAA is reduced, so is the production of NADH. If
PEPCK activity is high and OAA is continually used, MDH will continue to make OAA, in
addition to NADH. Therefore, the amount of NADH will directly reflect the activity of
PEPCK in this closed system.
Each liver cytosol was assayed at 0, 0.25, 0.5, 1, 2, 4, and 8mM malate, all run in
duplicate. One cuvette at a time, the following ingredients were added to a 3 mL acrylic
cuvette: 330 uL ddH2O, 300 uL 5mM MnCl2, 200 uL 10mM NAD+, 50 uL 1:50 MDH
(2.2mg/mL), and varying amounts of malate and 100mM Tris (see Table 1). The volume
in the cuvette after the addition of these ingredients totaled 1680 uL. The cuvette was
then incubated in a 37°C water bath for 3 minutes followed by the addition of 120 uL
liver cytosol and incubated for 1 minute in a 37°C water bath. The cuvette was removed
from the water bath, wiped on all sides with a Kimwipe, and placed in a Milton Roy
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Spectronic Genesys 5 spectrophotometer with a temperature controlled chamber set at
37°C. Finally, 200 uL 10mM GTP was added to start the reaction, bringing the final
volume in the cuvette to 2 mL. The absorbance at 340nm was recorded every 15
seconds for 2 minutes and the first 4 readings were used in the final calculation of
PEPCK activity.

Final Malate
Concentration in
Cuvette (mM)
0
0.25
0.5
1
2
4
8

Malate (uL)

100mM Tris (uL)

0
501
1001
2001
4001
8001
8002

800
750
700
600
400
0
0

Table 1. Final concentrations and volumes of malate for PEPCK assay. 110mM malate
stock, 220mM malate stock.

Solutions
CYTOSOL PREPARATION
Homogenization Buffer was prepared fresh for each set of 4 samples. The following
ingredients were added, one at a time, to a 150mL glass beaker:
20mL 0.5M potassium phosphate, pH 7.0
60mL doubly distilled H2O (ddH2O)
5mL 20mM EDTA
200uL 0.5mM leupeptin
2mL 50mM PMSF, dropwise
2mL 50mM DTT, dropwise
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The final volume was brought to 100mL with ddH2O and the solution was kept at room
temperature during liver cytosol preparation.
0.5M Potassium Phosphate, pH 7.0 was made by adding 13.609 g potassium
phosphate (MW=136.09 g/mol) to 150 mL ddH2O, stirring until dissolved, adjusting pH
to 7.0 with 10M NaOH, and bringing the final volume to 200 mL with ddH2O. The
solution was stored at 4°C.
20mM EDTA was made by adding 0.8089 g EDTA (MW=404.45 g/mol) to 90 mL
ddH2O, stirring until dissolved, and bringing the final volume to 100 mL with ddH2O. The
solution was stored at 4°C.
0.5mM Leupeptin was made by adding 0.0021 g leupeptin (MW=426.6 g/mol) to 10 mL
ddH2O, stirring until dissolved, and aliquoting 200 uL portions into Eppendorf tubes.
Aliquots were stored at -20°C.
50mM PMSF was made by adding 0.1742 g PMSF (MW=174.19 g/mol) to 18 mL
ethanol, stirring to dissolve, and bringing the final volume to 20 mL with ethanol. The
solution was stored at 4°C.
50mM DTT was made by adding 0.154 g DTT (MW=154.25 g/mol) to 18 mL ddH2O,
stirring until dissolved, and bringing the final volume to 20 mL with ddH2O. The solution
was stored at 4°C.
SPECTROPHOTOMETRIC ASSAY
5mM MnCl2 was made by adding 0.0989 g MnCl2 (MW=197.91 g/mol) to 100 mL
ddH2O and stirring until dissolved. The solution was stored at 4°C.
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10mM NAD was made by adding 0.1326 g NAD (MW=663.43 g/mol) to 20 mL ddH2O,
stirring until dissolved, and aliquotting 1.3 mL portions into Eppendorf tubes. The
aliquots were stored at -20°C.
1:50 Malate Dehydrogenase (MDH) from Bovine Heart was made fresh for each set
of 4 samples by adding 60 uL MDH (Sigma Aldrich, 2770 units/mg protein) to 2940 uL
0.9% NaCl, and vortexing briefly. The solution was kept on ice.
0.9% NaCl was made by adding 0.9 g NaCl (MW=58.44 g/mol) to 90mL ddH2O, stirring
until dissolved, and bringing the final volume to 100 mL with ddH2O. The solution was
stored at 4°C.
100mM Tris, pH 8.0 was made by adding 1.211 g Tris (MW=121.14 g/mol) to 80 mL
ddH2O, stirring until dissolved, adjusting the pH to 8.0 with 10M HCl, and bringing the
final volume to 100 mL with ddH2O. The solution was stored at 4°C.
10mM Malate was made by adding 0.0712 g malate (MW=178.05 g/mol) to 40 mL
100mM Tris and stirring until dissolved. The solution was stored at 4°C.
20mM Malate was made by adding 0.0712 g malate (MW=178.05 g/mol) to 20 mL
100mM Tris and stirring until dissolved. The solution was stored at 4°C.
10mM GTP was made fresh for each set of 4 samples by adding 0.0785 g GTP
(MW=523.2 g/mol) to 15 mL 100mM Tris and stirring until dissolved. The solution was
kept at room temperature.

Calculations
Beer’s law was used to calculate activity of PEPCK using the absorbance at
340nm. The equation calculates the activity of PEPCK as a rate, using the relationship
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A=Ebc, where A is absorbance at 340nm, E is the extinction coefficient of NADH
(6200L/mol x cm), b is the path length of the cuvette (1 cm), and c is the concentration
in mol/L. The volume in the cuvette must be accounted for, in this case 2 mL, in addition
to the volume of cytosol used, which was 120 uL. The following equation can be used to
express activity of PEPCK in umol/min/gram liver.

(Average A/min)
x
1 cm
x
106 umol/mol x 0.002L
6200 L/(mol x cm)
______________________________________________________________________
Liver (g) / buffer (mL)
1000 ul/mL

x

120 uL

PEPCK protein determination
To determine if the PBDE-driven suppression in PEPCK activity is due to a
reduction in PEPCK protein, western blotting methods were used in experiment 2.
Protein was extracted from liver samples stored frozen for approximately 1 week.

Protein extraction
Four samples were processed at a time. Liver samples were thawed, and
approximately 5mg tissue was dissected from each sample and placed into a 5 mL
plastic scintillation vial with 300 uL lysis buffer. Each sample was homogenized for
approximately 10 seconds with a Powerstat® polytron electric homogenizer set at 60.
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The blades of the homogenizer were washed with 600 uL lysis buffer into the cuvette
containing the sample, which was then transferred to a 1.5 mL Eppendorf tube.
Eppendorf tubes were maintained at a constant agitation on an orbital shaker for 2
hours at 4°C (in a walk-in refrigerator). The samples were then centrifuged for 20
minutes at 16,000 x g at 4°C in an Eppendorf 5418R tabletop centrifuge. The
supernatant was transferred into a clean Eppendorf tube using a 5 mL plastic transfer
pipette. Samples were kept on ice for immediate protein quantification using a
commercial DC protein kit (BioRad, Cat. No. 500-0112), and then frozen overnight for
use the next morning.

Western blot
A volume of sample equivalent to 25 ug total protein was mixed in a 3:1 ratio with
4X Laemmli sample buffer and boiled for 3 minutes at approximately 100°C.
Immediately after boiling, sample was loaded into a mini-protean TGX pre-cast 12-well
gel (BioRad, Cat. No. 456-9035). A protein plus dual color standard ladder (10-250 kD,
BioRad, Cat. No. 161-0374) was loaded into the first and last wells of each gel to
provide a molecular ladder as a point of reference. The second and eleventh wells
contained a positive control of rat liver extract (Santa Cruz, Cat. No. SC-271029). Wells
3-10 contained liver samples, in duplicate. A diagram of each gel was recorded, noting
how much sample, ladder, or positive control was added to the wells. Each gel was then
designated a number, and the numbers referred to the placement order of the gels in
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the electrophoresis cabinet. From the back of the cabinet to the front, the gels were
numbered 1, 2, and 3, and these numbers were indicated on the gel diagrams.
Gels were then placed in the electrophoresis cabinet containing approximately 1
liter of 1x tris-glycine/SDS running buffer. The cabinet was attached to a power source
set to 175 volts of electricity for approximately 45 minutes, allowing for the protein to run
down the gels and separate by size, with the largest proteins separating out first.
When the samples had run to the bottom of the gel, gels were removed from the
running buffer. The gels were removed from their outer plastic casing by forcing open
the plastic casing using the gel opening fork at the specified arrows. Once removed, the
bottom edge of each gel was cut off using a razor blade, and finally, gels were placed in
a bucket filled with approximately 1 L of 1x tris-glycine transfer buffer. Gels were placed
in the buffer and assembled in a transfer sandwich (described below) one at a time, to
ensure the identity of each gel was maintained.
Plastic cassettes were used to assemble transfer sandwiches. These cassettes
allow for the gels to be held in tight, close proximity to Immunoblot PVDF membranes
(BioRad, Cat. No. 162-0174), allowing for protein to transfer from the gels to the
membranes which would next be incubated with antibodies. One membrane at a time
was first incubated in methanol for 1 minute followed by pre-incubation in 1x transfer
buffer in a 5-liter plastic tub for 5 minutes. The membrane was then labeled, according
to which gel it would be incubated with. Once labeled, the membrane was placed into
the plastic tub containing a liter of transfer buffer along with the cassette, 2 foam
sponges, 2 transfer papers, and its corresponding gel. The sandwich was assembled
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starting with the black side of the cassette, followed by a sponge, a piece of transfer
paper, the gel, with lane 1 on the left side, membrane, another piece of transfer paper,
the other sponge, and finally the clear side of the cassette. After removal of all bubbles
from the sponges and from between the membrane and gel, the two white clips were
slid onto the top of the transfer sandwich to hold it together. Once one sandwich was
assembled, it was kept in the plastic tub containing the transfer buffer to avoid drying
out of the membrane, a key concern at all points of the procedure.
Once all three sandwiches were assembled, the first two were placed into one
electrophoresis cabinet containing one liter of 1x transfer buffer, and the third was
placed into a separate electrophoresis cabinet containing one liter of 1x transfer buffer.
An ice pack was added to the front of each cabinet along with a magnetic stir bar. The
cabinets were then placed on a large stir plate, allowing for constant stirring of the
transfer buffer overnight, while the cabinets were attached to a power source set to 30
volts of constant power.
Approximately 21 hours after start of the transfer process, the cabinets were
disconnected from the power supply and the contents of the cabinets were emptied
back into the plastic tub that was originally used for cassette assembly. Once in the
bucket, sandwiches were disassembled and membranes were immediately transferred
to individual small dishes containing phosphate buffered saline (PBS) solution with 10%
w/v non-fat dry milk and 1:500 dilution PEPCK-specific primary antibody (Santa Cruz,
Cat. No. SC-271029). After 1-hour incubation with primary antibody, the membranes
were washed three times for 10-minute increments in PBS containing 10% non-fat dry
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milk. After washing, the membranes were incubated for another 1-hour period in a light
sensitive goat anti-mouse IgG secondary antibody (Licor, Cat. No. 827-08364), at a
1:15,000 dilution, according to manufacturer instructions. The membranes were once
again washed three times for 10-minute increments to remove any excess, unbound
secondary antibody. The secondary antibody bound to primary antibody, providing a
fluorescent tag that was then visualized using a Li-Cor Odyssey scanner.
To visualize PEPCK on the membranes, the Li-Cor Odyssey scanner was used
with all lights turned off and room shades closed. Membranes were placed one at a
time, face down on the front left corner of the scanner. Bubbles were then pressed out
from under the membrane using a 3-inch rubber roller, a rubber cover was placed on
top of the membrane, and the scanner cover was closed. The scanner was then
instructed to visualize the membrane, producing a picture that was sent to the computer
and saved as a .tif file to a USB drive. This process was repeated for all 3 membranes.
Pictures were then used to calculate density of each PEPCK band on the 3 membranes
using the Un-Scan-It computer densitometry program. This provided semi-quantitative
data regarding overall PEPCK protein present in the samples.

Solutions
Homogenization Buffer was made by adding the following ingredients to a half liter
glass bottle in the order listed:
12.5 mL 1M HEPES
2.2 g NaCl
0.105 g NaF
0.5 mL 500mM EDTA
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25 mL glycerol
1.25 mL Triton X-100
Bring the final volume to 250 mL using ddH2O
The solution was made the day prior to protein extraction and stored at 4°C for
approximately 2 weeks.
Lysis Buffer was made by placing 15 mL homogenization buffer into a 20 mL glass
beaker and adding 150 uL aprotinin (Sigma Aldrich, Cat. No. A6279, 3-7 TIU/mg
protein) and 150 uL 1M benzamidine. Buffer was kept on ice for the duration of the
protein extractions.
1M HEPES was made by adding 3.098 g HEPES (MW=238.3 g/mol) to about 10 mL
ddH2O, stirring until dissolved and bringing final volume to 13 mL with ddH2O.
1M Benzamidine was made by adding 0.018 g benzamidine (MW=120.15 g/mol) to
150uL ddH2O and mixing well until dissolved. The solution was immediately added to
the lysis buffer.
4X Laemmli Buffer was combined with 2-mercaptoethanol per manufacturer instruction
(BioRad, Cat. No. 161-0737).
Running Buffer (tris-glycine/SDS) was made by adding 100 mL 10X tris-glycine/SDS
(BioRad, Cat. No. 161-0732) to 900 mL ddH2O and mixing well. Buffer was made the
morning of use and was stored at 4°C until needed.
Transfer Buffer (tris-glycine) was made by adding 200 mL methanol to 700 mL
ddH2O, followed by the addition of 100 mL 10X tris-glycine (BioRad, Cat. No. 161-0734).
The solution was then mixed well. Buffer was made the morning of use and was stored
at 4°C until needed.
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Phosphate-Buffered Saline (PBS) was made by adding 100 mL 10x-PBS (BioRad,
Cat. No. 161-0780) to 900 mL ddH2O and mixing gently. Buffer was made the morning
of use and was stored at 4°C until needed.

Glyceroneogenesis
To address the hypothesis that PBDE treatment at 14 mg/kg BW for 28 days
suppresses hepatic glyceroneogenesis, fresh liver tissue was used to quantify hepatic
glyceroneogenesis using a radioactive method in experiment 2.
Glyceroneogenesis samples were transported back to the lab on ice, where each
of the 3 samples was placed in 1 well of a 6-well plate. Each well had 1.5mL Kreb’sRinger-Bicarbonate buffer (KRB) containing 5mmol glucose. Holding each sample
above its well, it was cut in ~10, 20mg pieces using tweezers and small dissecting
scissors. Each well was gassed with 95% CO2, 5% O2 and incubated on a shaker at
37°C for 6 hours.
Approximately 30 minutes before the end of incubation, the radioactive working
solution was made. Once the 6-hour incubation was complete, a Pasteur pipette was
used to remove the KRB from each well, followed by addition of 1.5mL working solution
to each well. Wells were then gassed with 95% CO2, 5% O2 and incubated on a shaker
for 2 hours at 37°C, allowing for incorporation of 14C-pyruvate into the glycerol backbone
of triglycerides in the liver tissue. At the end of this incubation period, a Pasteur pipette
was used to remove the radioactive working solution from each well, and wells were
filled with cold KRB, halting metabolism of the tissues. The KRB was removed using
5mL plastic syringes, and then 1.5mL phosphate-buffered saline (PBS) was added to
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each well for washing purposes. Each sample set was then transferred to another 6-well
plate containing 1.5mL PBS per well. The plate was agitated lightly, followed by transfer
of samples to another plate with clean PBS. This was repeated four times total, allowing
for an initial PBS wash in the incubation plates, followed by four consecutive washes in
clean 6-well plates. After washing was complete, each sample was removed from its
well and placed in a 1.5mL Eppendorf tube, ensuring all pieces of sample congregated
at the bottom of the tube. Tubes were then snap frozen in liquid nitrogen and placed in a
-20°C freezer for later fat extraction.
Three-50uL aliquots of the extra working solution were removed and counted for
determination of specific activity after each set of samples was incubated and frozen.
Each aliquot was placed into an individual plastic scintillation vial, followed by immediate
addition of 3 mL Optiphase Supermix scintillation cocktail. Vials were labeled and
counted on the scintillation counter to quantify disintegrations per minute in each
sample, which was then used to calculate specific activity of the working solution.

Extraction of fat for radioactive quantification
Within 3-4 weeks of initial sample incubation and freezing, fat was extracted and
radioactivity incorporated into fat was quantified as a marker of glyceroneogenesis. The
three samples from one animal were removed from the freezer and transferred, frozen,
from the base of the eppendorf tubes into three respective glass homogenizing tubes,
each containing 1 mL ddH2O. Each sample was homogenized 6 times up and down
using a hand drill and homogenizing pestle, and then transferred into a 15 mL capped-
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glass centrifuge tube containing 0.25 mL chloroform. Samples were mixed by hand
briefly and then transferred back to their individual homogenization tubes where they
were homogenized three more times up and down. Samples were transferred back to
the capped-glass centrifuge tubes, and 3.75 mL methanol:chloroform 2:1 was added.
Every step was completed on ice, in the hood. Tubes were then capped and vortexed
for 30 seconds before shaken mildly on ice for 30 minutes.
After 30 minutes of incubation, samples were taken off the shaker and placed on
ice in the hood, where 1.25 mL chloroform was added to each tube before re-capping
and mild shaking on ice for another 10 minutes. At the end of the second incubation,
samples were taken off the shaker once again and placed on ice in the hood, where 1
mL ddH2O was added to each tube before re-capping and shaking on ice for an
additional 10 minutes. At the end of the final 10-minute incubation, samples were
balanced against water and centrifuged at 478 x g (3000 rpm) for 15 minutes at 4°C in a
Sorvall Evolution RC centrifuge. After centrifugation, 2-1 mL portions of the bottom,
chloroform layer from each sample were removed and transferred into individual 5 mL
plastic scintillation vials, immediately followed by the addition of 3 mL Optiphase
Supermix scintillation cocktail. Vials were labeled and counted on the scintillation
counter to quantify disintegrations per minute within each sample, which was then used
to calculate the rates of glyceroneogenesis.
Extractions were overlapped to optimize time spent on the procedure; however
only 3 sets of triplicate samples could be run at once. The second set of samples was
not removed from the freezer until the timer for the first set read 13 minutes remaining
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for the 30-minute incubation. Similarly, the third set was removed from the freezer when
the timer for the second set read 13 minutes remaining for the 30-minute incubation.
This was to ensure that at the end of the third incubation, the samples could go directly
into the centrifuge without any lag time. Preliminary studies revealed that a lag between
incubation and centrifugation caused a dramatic drop in radioactivity, skewing the data.
It was also important to remove the 2-1 mL aliquots from each sample tube within the
first 2 minutes of removal from the centrifuge, to ensure that the aliquots reflected
optimal separation of fat from other components of the liver samples. If this transfer took
any greater than 2 minutes, the top layer started to fall back into the bottom layer,
causing a distinct difference in radioactivity between the first and third triplicate samples.

Solutions
Kreb’s-Ringer-Bicarbonate Buffer (KRB) was made by adding the following amounts
of each stock solution in the order listed, and stored at 4°C for up to 1 week:
500 mL ddH2O
25 mL 1M HEPES
62.5 mL 2M NaCl
5 mL 1m KCl
1 mL 1M KH2PO4
1.25 mL 1M MgCl2-6H2O
1.25 mL 1M CaCl2-2H2O
25 mL 1M NaHCO3
pH to 7.4, bring to final volume of 1 Liter with ddH2O
Stock solutions were made as follows and stored at 4°C for approximately 6-8 weeks:
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1M HEPES was made by adding 119.15 g HEPES (MW=238.3 g/mol) to about 450 mL
ddH2O and stirring until dissolved. The pH of the solution was adjusted to 7.76 and the
final volume of the solution was brought to 500 mL with ddH2O.
2M NaCl was made by adding 58.44 g NaCl (MW=58.44 g/mol) to approximately 450
mL ddH2O, stirring until fully dissolved, and bringing the final volume to 500 mL with
ddH2O.
1M KCl was made by adding 7.46 g KCl (MW=74.6 g/mol) to approximately 90 mL
ddH2O, stirring until fully dissolved, and bringing the final volume to 100 mL with ddH2O.
1M KH2PO4 was made by adding 13.609 g KH2PO4 (MW=136.09 g/mol) to
approximately 90 mL ddH2O, stirring until fully dissolved, and bringing the final volume
to 100 mL with ddH2O.
1M MgCl2-6H2O was made by adding 20.33 g MgCl2-6H2O (MW=203.30 g/mol) to
approximately 90 mL ddH2O, stirring until fully dissolved, and bringing the final volume
to 100 mL with ddH2O.
1M CaCl2-2H2O was made by adding 14.702 g CaCl2-2H2O (MW=147.02 g/mol) to
approximately 90 mL ddH2O, stirring until fully dissolved, and bringing the final volume
to 100 mL with ddH2O.
1M NaHCO3 was made by adding 42.005 g NaHCO3 (MW=84.01 g/mol) to
approximately 450 mL ddH2O, stirring until dissolved, and bringing the final volume to
500 mL with ddH2O.
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C-pyruvate was ordered from Perkin Elmer (Cat. No. NEC2550, 50 uCi) in powder

form. To reconstitute into solution, 2 uL ddH2O was added for every uCi of radioactivity
present.
Working Solution was made fresh for each set of 4 livers (liver samples were run in
triplicate; working solution made for 12 samples at a time). First, 19 mL cold KRB was
added to a 50 mL glass beaker. The beaker was placed on a heating stir plate followed
by the addition of 10.45 mg pyruvic acid and a magnetic stir bar. Solution was stirred
until the pyruvic acid dissolved, followed by addition of 380 mg fatty acid free bovine
serum albumin (FAF-BSA) (Sigma, Cat. No. A7030). The hot plate was turned on low
and stirring was continued until FAF-BSA was completely dissolved. Hot plate was then
turned off while stirring was continued for the final addition of 38 uL 14C-pyruvate (or 1
uCi 14C-pyruvate per mL working solution). The final working solution was stirred for an
additional 5 minutes to ensure mixing.

Phosphate-Buffered Saline (PBS) was made by adding 100 mL 10x-PBS (BioRad,
Cat. No. 161-0780) to 900 mL ddH2O and mixing gently. The solution was stored at 4°C
for approximately 3 weeks.

Methanol:Chloroform 2:1 was made by adding 90 mL methanol to a 150 mL amber
glass bottle, followed by the addition of 45 mL chloroform. The mixture was then
vortexed for 15-30 seconds, capped, and stored under the hood.
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Calculations
Glyceroneogenesis Rate of each sample was expressed as pmol 14C-pyruvate
incorporated into triglyceride per hour per mg tissue (pmol/hr/mg). Specific activity (SA)
was calculated every time fresh working solution was made, and was used to convert
dpm into nmol per mL, because 1mL of the chloroform layer was counted at a time. The
chloroform layer was approximately 2.5mL per sample, so multiplication by 2.5 allowed
for the number to be expressed in nmol/whole sample. Amount of time in incubation and
sample weight were also accounted for to express glyceroneogenesis as a rate in
nmol/hr/mg tissue. The final rate was multiplied by 1000 to express the rate in
pmol/hr/mg tissue. The following equation is a mathematical representation of the
calculation used:

1000 pmol/nmol *{(dpm of sample/SA of working solution in dpm/nmol) *2.5mL/sample}
(2 hours per incubation x sample weight in mg)
Each sample was counted in duplicate, and each animal had triplicate tissue
samples analyzed. The duplicate rates were averaged for a within sample mean. The
triplicate means were then averaged for a within animal mean. The within animal means
were then averaged for a within treatment group mean.
Specific activity (SA) was calculated using the specific activity of the stock
solution of 14C-pyruvate, which was 9.5mCi per mmol for a bottle containing 50uCi. This
corresponds to .005mmol of radioactive pyruvate in the stock solution. Working solution
is made by adding 19uCi of 14C-pyruvate, which is 38% of the total stock, containing
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.00199mmol of radioactive pyruvate, or 1.99umol. The addition of 10.45mg cold
pyruvate added 118.74umol cold pyruvate, for a total of 120.74umol pyruvate in 19mL
working solution. Three aliquots of 50uL were counted of each working solution, which
were then averaged to provide one value representing dpm/50uL, which was then used
to calculate SA for each sample using the following mathematical relationship:
dpm
0.050mL

X

19mL
120.74umol

=

(dpm/umol) x 1000 = dpm/nmol

SA was calculated separately for each working solution that was made, and applied to
the corresponding samples when calculating glyceroneogenesis rates.

Liver lipid content
To evaluate PBDE-associated changes in hepatic lipid content, triglycerides were
extracted from frozen livers of rats in experiment 2. Liver portions were allowed to thaw,
three at a time, on ice for approximately 30-60 minutes. At room temperature, three 50
mg portions of each liver were weighed out, weights recorded, and samples individually
homogenized ten times up and down in 0.3 mL cold PBS. The solution was left to rest
for 15 seconds followed by homogenization 5 additional times up and down. Each
sample was then transferred to an individual clean, 15 mL Corex glass tube. To ensure
as much sample transfer as possible, 2 mL hexane:isopropanol (3:2) solution was
added to the homogenization tube, mixed lightly by hand and transferred to the Corex
tube containing the sample. Each sample was then gassed with nitrogen and vigorously
shaken for 1 hour. Next, 0.6 mL 0.5M sodium sulfate was added to each sample. Tubes
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were then vortexed for 60 seconds, and vigorously shaken for an additional 15 minutes.
After the final shake period, samples were balanced against water and centrifuged for
10 minutes at 871 x g (2700 rpm) and 23°C in a Sorvall Evolution RC centrifuge.
Immediately following centrifugation, 1-1 mL aliquot of the upper phase from each
sample was removed and placed in a dry, pre-weighed disposable glass tube. The
samples were then dried under nitrogen gas for approximately 20 minutes and weighed
again immediately, and then once more the following day to confirm complete drying.
The change in weight of the tube was then used to calculate the percentage of lipid
present in each liver.

Solutions
Phosphate buffered saline (PBS) was made by adding 10 mL 10x-PBS (BioRad, Cat.
No. 161-0780) to 90 mL ddH2O and mixing gently. The solution was stored at 4°C for
approximately 3 weeks.
Hexane:Isopropanol (3:2) was made by adding 60 mL hexane to an amber glass
bottle under the hood, followed by adding 40 mL isopropanol, capping, and vortexing
lightly for approximately 15-30 seconds. The solution was stored under the hood.
0.5M sodium sulfate was made by placing 7.102 g sodium sulfate (MW=142.04 g/mol)
in ddH2O and bringing the final volume to 100 mL. The solution was mixed on a stir
plate using a magnetic stir bar for approximately 5-10 mintues. The solution was stored
at 4°C for approximately 3 weeks.
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Calculations
The following calculation was used to determine hepatic lipid percentage:

{ 6/5* x [(final tube weight – initial tube weight) /initial weight of sample] }x 100

*6/5 is a correction factor for volume of hexane. The lipid is collected in the hexane
layer, and 2 mL of 3:2 hexane:isopropanol is added to each tube, equaling a theoretical
volume of 1.2 mL hexane. Only 1 mL of this is extracted and used in the final step of the
method, and therefore, to account for the amount of lipid extracted in the whole volume
of hexane, the raw calculated values are multiplied by (1.2/1) or (6/5).
Samples were run in triplicate, therefore three lipid percentages were calculated for
each liver. Coefficient of variation (CV) was conducted within the three samples for each
liver, and the data was rejected if the CV was greater than 25%. In these cases, three
additional samples were taken from the liver and the method was repeated.

STATISTICS
Coefficient of variation of 25% for PEPCK activity calculated from the literature
(Chauvin et al., 1996) requires 8 rats per group to detect a 45% treatment effect
(Berndtson, 1991). Based on this calculation, 16 animals were used for experiment 1,
n=8 per group. Coefficient of variation of 10% calculated from pilot studies for
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glyceroneogenesis requires 6 rats per group to detect a 20% treatment effect
(Berndtson, 1991). Based on this calculation, 12 animals were used for experiment 2,
n=6 per group.
Two-way ANOVA was used to determine the effect of treatment and experiment
date on body and liver weight outcomes using JMP Pro11.
Unpaired t-tests were used to compare means for CON and TRT groups for
blood metabolites, PEPCK protein density, glyceroneogenesis, and liver lipid
percentage using GraphPad InStat 3. Equal population standard deviations were
assumed in all tests.
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CHAPTER 3

PBDE-INDUCED SUPPRESSION OF
PHOSPHOENOLPYRUVATE CARBOXYKINASE (PEPCK)
DECREASES HEPATIC GLYCERONEOGENESIS AND
DISRUPTS HEPATIC LIPID HOMEOSTASIS

INTRODUCTION

	
  

Polybrominated diphenyl ethers (PBDEs) are a class of environmental chemicals

added to consumer products starting in the 1970s to help reduce flammability (Watkins
et al., 2011, Besis and Samara, 2012). PBDEs have been used in a wide variety of
products, including but not limited to electronics, textiles, curtains, couches and many
other types of home and office furniture and upholsteries (Harrad et al., 2008, JonesOtazo et al., 2005, Wilford et al., 2005).
Because PBDEs are added, not bound, to the products in which they are used,
they freely migrate into the air and settle into the environment (Costa et al., 2008).
When consumer products containing these chemicals are disposed of, either in landfills
or through incineration, PBDEs will settle into sediment, sludge, and soil, where they
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can contaminate the water and food supply and eventually biomagnify up the food chain
(Osako et al., 2004, Hale et al., 2008, Costa et al., 2008).
The main routes of human exposure to PBDEs include inhalation and ingestion,
with sources coming mainly from dust (Harrad et al., 2008), but also food sources such
as fish, dairy, and meat (Costa et al., 2008). Once in the body, PBDEs tend to reside in
the fat tissue due to their lipophilicity (Johnson-Restrepo et al., 2005), however
metabolism of PBDEs occurs in the liver (Stapleton et al., 2009), suggesting these two
tissues bear the bulk of the PBDE exposure burden.
Although PBDEs have been phased out of production since late 2013, they still
persist in the environment. Homes and offices have furniture and upholsteries
containing PBDEs, and disposal of these products continue to contaminate both indoor
and outdoor environments.
Once inside the body, PBDEs are known endocrine disruptors. Due to the
similarity in structure between PBDEs and thyroxine, PBDEs are able to competitively
bind thyroid receptors α and β (Meerts et al., 2000), thyroid transporter transthyretin
(Hamers et al, 2006, Marchesini et al., 2008), and effectively decrease circulating levels
of the active form of thyroid hormone, triiodothyronine (Lee et al., 2010, Tseng et al.,
2008). PBDEs have also been found to bind receptors for estrogen, progesterone,
androgens, and glucocorticoids (Hamers et al., 2006), disrupting endocrine signaling
and potentially creating obesogenic or diabetic effects (Feo et al., 2013).
In addition to endocrine-disruption, PBDEs largely affect the liver by increasing
oxidative stress and antioxidant enzyme activity (An et al., 2010, Albina et al., 2010),
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increasing fatty deposition in the liver (Bruchajzer et al., 2010), and decreasing activity
of a key metabolic enzyme, phosphoenolpyruvate carboxykinase (PEPCK). Indeed,
Nash et al. (2013) found that hepatic PEPCK activity was suppressed by 43% when
male Wistar rats were exposed to 14mg/kg/day DE-71, a commercial PBDE-mixture, for
28 days. This change in enzyme activity was accompanied by an increased
glucose:insulin ratio, suggesting metabolic perturbations indicative of insulin resistance.
PEPCK catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate
(PEP), a regulated and crucial beginning step of both de novo glucose synthesis via
gluconeogenesis, and triglyceride resynthesis via glyceroneogenesis (Yang et al.,
2009). Increased enzyme activity is necessary for these pathways to be robust during
fasting, and the primary mechanism for controlling PEPCK activity is via increased
transcription (Chakravarty et al., 2005, Yang et al., 2009).
Reduced PEPCK activity has been associated with physiological consequences,
such as decreased hepatic gluconeogenesis (Zhang et al., 2012, Diani-Moore et al.,
2013) and changes in glucose:insulin ratio (Nash et al., 2013). These findings suggest
decreased PEPCK activity may be associated with perturbed hepatic carbohydrate
metabolism. Less explored is how changes in PEPCK may be affecting
glyceroneogenesis and consequently, hepatic lipid metabolism. Because
glyceroneogenesis generates glycerol-3-phosphate, the necessary backbone for fatty
acid esterification, disruption of this pathway could lead to decreased triglyceride
formation and increased hepatic and systemic fatty acid levels. Chronically high levels
of fatty acids have been shown to perturb insulin signaling, leading to the development
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of insulin resistance and playing a potential role in the development of diabetes. Thus,
the goal of the current study was to examine PBDE-induced alterations of hepatic
glyceroneogenesis and PEPCK expression, and the resulting implications for hepatic
lipid metabolism.

MATERIALS AND METHODS

Animals
Twenty-eight weanling male Wistar rats (Charles River Laboratory, Wilmington, MA)
were used for this study. Rats weighed between 75-100 g at arrival and were allowed to
acclimate to their new environment for 5-8 days. They were housed individually in
stainless steel hanging basket cages under a 12 h light/dark cycle and fed standard rat
chow and water ad libitum. Procedures and methods were approved by the University of
New Hampshire Institutional Care and Use Committee (#131003 and #14071).

Chemicals
DE-71 was generously donated from NIEHS (Lot# 1500K07A) and Indiana University
(Lot# G550QF65A). Approximately 2 grams were dissolved in hexane and corn oil;
excess hexane was evaporated under nitrogen for a final PBDE concentration of 14
mg/mL. Control solution was prepared with identical amounts of hexane using the same
procedure, without the addition of DE-71.
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Treatment
All rats were gavaged daily with 14 mg/kg body weight DE-71 (n=14, TRT) or a
comparable amount of corn oil vehicle (n=14, CON) between 8:00-10:00 AM, for 28
days. On days 27 and 28, rats were fasted and then euthanized between 8:00-10:00
AM on the morning of day 29. Rats were weighed every 3 days throughout the
experiment. The study included two experiments with identical treatment methods
conducted nine months apart, using lot #1500K07A for the first experiment and lot
#G550QF65A for the second experiment.

Tissue Procurement
After the 48-hour fast, rats were weighed then euthanized via CO2 asphyxiation. Three
to five mL of blood were collected immediately via cardiac puncture, followed by removal
of the liver. Livers were rinsed, blotted dry, and weighed. Each liver was separated into
two 5 mg-portions that were fixed in formalin for histological analysis, three 200 mgportions that were placed on ice for glyceroneogenesis measurements, and three to five
2 gram-portions that were snap frozen in liquid nitrogen and stored at -20°C for later
quantification of PEPCK protein, PEPCK activity, and hepatic lipids.

Serum Metabolites
Blood was allowed to clot at room temperature for approximately 2 hours, and then
centrifuged at room temperature for 15 minutes at 1200 x g. Serum was separated and
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frozen at -20°C, until analysis by Marshfield Laboratories (Marshfield, WI) for blood
metabolites.
Histological Analysis
Formalin-fixed livers were sectioned, mounted on glass slides and stained with
hematoxylin and eosin for evaluation of lipid content using light microscopy by the NH
Veterinary Diagnostic Lab at the University of New Hampshire.

PEPCK Protein
Liver was thawed on ice and protein was extracted from a 5 mg-portion by
homogenization in 300 uL of lysis buffer containing 50mM Hepes, 150mM NaCl, 10mM
NaF, 1mM EDTA, 10% glycerol, 0.5% Triton X-100, 1% aprotinin (3-7 TIU/mg protein)
and 10mM benzamidine. The blade was rinsed with 600uL lysis buffer, which was
added to the sample, and samples were maintained at a constant agitation on an orbital
shaker for 2 hours at 4°C. Finally, samples were centrifuged for 20 minutes at 16,000 x
g and 4°C. Supernatant was assayed for protein (DC protein kit, BioRad), and frozen
overnight for use the next morning.
Twenty-five ug protein from each sample was loaded in duplicate onto miniprotean pre-cast gels (BioRad) and separated via 10% SDS-PAGE before transfer onto
Immuno-blot PVDF membranes (BioRad). Membranes were incubated for one hour
with a mouse PEPCK primary antibody, 1:5000 dilution (Santa Cruz Biotechnology,
Dallas, TX), washed with PBS containing 10% nonfat dry milk to remove excess
unbound antibody, incubated for one hour with a light-sensitive goat anti-mouse IgG
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secondary antibody (LiCor), and washed with PBS containing 10% nonfat dry milk. Gels
were visualized using a Li-Cor Odyssey Scanner and semi-quantified using
densitometry (Un-Scan-It).

PEPCK Activity
Enzyme activity was measured as previously described (Nash et al., 2013) with
modifications. Approximately 2-gram portions of each liver were homogenized and
centrifuged at 3116.425 x g (5000 rpm) for 15 minutes at 4°C, and the cytosolic fraction
was isolated by centrifugation at 59466 x g (30,000 rpm) for 60 minutes at 4°C. PEPCK
activity was measured in a 3 mL cuvette with final concentrations of 50mM Tris, 0.75mM
MnCl2, 1mM NAD+, 6 units MDH, 1mM GTP, and 0-8 mM malate (final volume was 2
mL) as follows: the cuvette was incubated for 3 minutes at 37°C containing doubledistilled water, MnCl2, NAD+, MDH, malate and Tris, pH 8.0; cytosol was added and
incubation continued for another minute; GTP was added to start the reaction. The
samples were read at 340nm every 15 seconds for 2 minutes, and the average ΔOD
was calculated for the first minute. Samples were run in duplicate with 0, 0.25, 0.5, 1, 2,
4, and 8mM malate.

Hepatic Lipids
Livers were thawed on ice and lipids extracted as described by Nash et al. (2013).
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Hepatic Glyceroneogenesis
Hepatic glyceroneogenesis rates were measured as described previously (Jaubert et
al., 2012) with modifications. In brief, each of three 200 mg-portions of liver was cut into
approximately 10 pieces, and placed in one well of a 6-well plate containing 1.5 mL
Krebs Ringer bicarbonate buffer containing 5mM glucose. Samples were incubated for 6
hours at 37°C, followed by removal of media using glass Pasteur pipette. Each well was
then incubated in 1.5mL Krebs Ringer bicarbonate buffer containing 6.25 mM pyruvic
acid, 2% fatty acid free BSA, and 1.5 uCi 14C-pyruvate at 37°C. After 2 hours, samples
were rinsed 6 times in cold PBS, placed in 1.5mL Eppendorf tubes, snap frozen in liquid
nitrogen, and stored at -20°C for up to 2 weeks. Fat was extracted from frozen samples
by the following steps, all on ice: each sample was homogenized in 1mL double distilled
water for 5 strokes, 0.25mL chloroform was added and sample homogenized for 3
strokes, 3.75 mL methanol:chloroform 2:1 was added and sample shaken for 30
minutes. Next, 1.25mL chloroform was added and the sample was shaken for 10
minutes, followed by the addition of 1 mL ddH2O and 10 minutes of shaking. The
samples was centrifuged for 15 minutes at 478 x g and 4°C, and two 1mL-portions of
the bottom phase of each sample were removed and counted in a scintillation counter to
calculate incorporation of 14C-pyruvate into hepatic lipids.
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Statistics
A two-way ANOVA was used to evaluate the effect of treatment and time of experiment
on body weight and liver weight. Means for CON and TRT groups for blood metabolites,
hepatic PEPCK Vmax and Km, hepatic lipids, hepatic glyceroneogenesis, and hepatic
PEPCK protein were compared using unpaired t-tests, assuming equal population
standard deviations using GraphPad InStat3 and JMP Pro 11. Significance was set as
P<0.05.
RESULTS

Animal and Liver Measurements
Analysis of final body weight, liver weight, and liver as a percent of body weight
for rats in both experiments revealed no effect of time of experiment, but a significant
effect of treatment (Table 2). DE-71 treatment increased liver weight by 33% and liver
weight as a percent of body weight by 26%, but did not have an effect on final body
weight. Furthermore, DE-71 treatment increased hepatic concentrations of BDE-47,
BDE-99, and BDE-100 by 59-, 31-, and 80-fold, respectively (Table 3).

Hepatic PEPCK Activity
Hepatic PEPCK activity from CON vs. TRT rats demonstrates a 28% decrease of
activity in livers from TRT rats compared to CON at the highest substrate concentration
of 8mM (Figure 2). Kinetics curves of PEPCK activity from individual rat livers were
plotted on Sigma Plot 12, and a hyperbolic curve was fit to the data and used to
determine individual hepatic PEPCK Km and Vmax, revealing a 40% decrease in Vmax
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of TRT animals compared to CON, with no change in Km between treatment groups
(Table 4).

Hepatic PEPCK Protein Levels
A representative Western blot of hepatic PEPCK protein levels in TRT and CON
samples is shown in Figure 4. Quantification of the data (n=6 per group) using
densitometry revealed a 17% decrease in PEPCK protein in livers of TRT rats
compared to CON (p=0.11). A Q-test revealed no clear outliers due to the limited
sample size; however samples that skewed coefficient of variation by greater than 25%
were removed from the comparison. Removal of one CON and one TRT point tightened
coefficient of variation by 34% and 28%, respectively, and comparisons of the new
means revealed a significant, 23% decrease in PEPCK protein in livers of TRT animals
compared to CON (p<0.05, n=5).

Blood Metabolites
To evaluate if PBDE-induced PEPCK suppression affected hepatic
gluconeogenesis, serum glucose was measured. TRT animals exhibited a 48%
reduction in serum glucose compared to CON, after a 48-hour fast (Table 5). Betahydroxybutyrate, a marker of excess unesterified fatty acid metabolism, was significantly
increased by 27% in TRT animals compared to CON (p<0.05). This was accompanied
by a significant 27% reduction in serum triglycerides in TRT animals. Serum NEFA and
cholesterol levels were not different between the two groups.
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Hepatic Lipid Content
Hepatic lipid was 29% lower in livers from TRT animals compared to CON
(p<0.05, Figure 5). In contrast, histological data illustrated mild lipid vacuolation in the
midzonal region of livers from 7 of the 8 TRT rats, and 0 of the 8 CON rats (Figure 6).

Hepatic Glyceroneogenesis
There was a significant, 41% decrease in hepatic glyceroneogenesis in livers of
TRT animals compared to CON (Figure 7). The change in glyceroneogenesis was not
dependent on liver location because triplicates were run from three distinct areas of
each liver and there were no significant differences between triplicate samples within
each treatment group.

DISCUSSION
This study is the first to evaluate hepatic lipid metabolic perturbations caused by
the commercial PBDE-mixture, DE-71, revealing that PBDEs suppress hepatic
glyceroneogenesis in vitro. This suppression is consistent with our findings of reduced
hepatic PEPCK protein and activity. To our knowledge, this is the first study to (1)
address hepatic glyceroneogenesis in response to PBDE exposure, and (2) illustrate a
relationship between hepatic PEPCK protein, activity, and glyceroneogenesis.
Despite the lack of evidence supporting a decrease in glyceroneogenesis in
response to PBDE exposure, other work in the liver suggests that hepatic
glyceroneogenesis is responding to changes in hepatic PEPCK activity (Martins-Santos
et al., 2007), which has been shown to be suppressed by DE-71 exposure (Nash et al.,
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2013). Martins-Santos et al. (2007) incubated precision-cut liver slices from control and
48 h-fasted rats with 14C-glucose, 14C-pyruvate, and 14C-glycerol to measure the
contribution of gluconeogenesis, glyceroneogenesis, and glycerol phosphate to the
production of glyceride-glycerol in the liver. They found up to a 43% increase in 14Cincorporation from pyruvate in fasted animals compared to controls, supporting an
increase in hepatic glyceroneogenesis in the fasted state. Furthermore, Martins-Santos
et al. (2007) found an accompanying 84% increase in hepatic PEPCK activity,
suggesting glyceroneogenesis responds to changes in hepatic PEPCK activity. This
provides evidence to support that the PBDE-induced decrease in hepatic PEPCK
activity shown by Nash et al. (2013) may be sufficient to suppress hepatic
glyceroneogenesis, which our current data demonstrate.
Furthermore, a recent study conducted by Jaubert et al. (2012) suggested a
correlation between PEPCK protein and glyceroneogenesis in the adipose tissue in
vitro, another finding supported by the current data. Although other work in the adipose
tissue contradicts a clear relationship between PEPCK protein, PEPCK activity, and
glyceroneogenesis (Nye et al., 2008), it is important to note that this work was done in
vivo, adding methodological complications that are not seen in in vitro models.
Additionally, PEPCK activity in the adipose tissue is decreased by glucocorticoids, while
PEPCK activity in the liver is increased by glucocorticoids (Chakravarty et al., 2005),
suggesting adipose and liver glyceroneogenesis may not be comparable. The current
work illustrates that PBDE exposure does indeed decrease hepatic glyceroneogenesis
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in addition to hepatic PEPCK protein and activity, supporting a correlation between
PEPCK protein, PEPCK activity, and glyceroneogenesis in the liver.
Suppression of glyceroneogenesis seen in the current study in response to DE71 treatment is expected to cause a lack of glycerol backbone for fatty acid
esterification, and a subsequent rise in hepatic non-esterified fatty acids (NEFA).
Although we did not measure hepatic NEFA directly, we did measure a significant rise in
circulating ketones, suggesting PBDE treatment increased NEFA availability in the liver.
It is well established that ketone synthesis is a substrate driven, hepatic pathway
dependent on the amount of available NEFA. Once NEFA are delivered to the liver in
times of increased lipid mobilization due to fasting, the degree to which ketone synthesis
occurs varies, based on the apportioning of those NEFA between oxidation and
esterification (Nguyen et al., 2008). Disruptions in the liver’s ability to esterify excess
NEFA due to suppressed glyceroneogenesis, likely causes a large increase in NEFA
oxidation and subsequently, ketogenesis, due to the lack of alternate uses for NEFA
within the liver.
Changes in circulating ketones, likely due to suppressed glyceroneogenesis,
have been associated with suppression of PEPCK activity, further supporting the
relationship between glyceroneogenesis and PEPCK. Ablation of whole body PEPCK in
mouse models was sufficient to significantly increase circulating ketones by 3-fold
(Hakimi et al., 2005). Silencing of just the mitochondrial form of PEPCK in livers and
kidneys of rats was also sufficient to increase circulating ketones by 18% (Stark et al.,
2014). No change was exhibited in these or the current study in circulating NFEA levels,
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although this is not unexpected. Both CON and TRT animals in the current study were
fasted for 48 hours before euthanasia, and changes in circulating NEFA levels between
the fed and 48 hour fasted state do not drastically change (Syamsurnarno et al., 2013),
despite marked increases in overall energy and lipid metabolism (Sokolovic et al.,
2008). This suggests NEFA are transient and circulating levels may not reflect liverspecific changes in metabolism.
Another key finding that exemplifies metabolic disruption by suppressed PEPCK
and glyceroneogenesis is the PBDE-induced decrease in circulating triglycerides. This,
coupled with the finding that PBDE treatment reduced liver lipids, suggests that PBDE
decreased the liver’s ability to synthesize triglycerides by suppressing hepatic PEPCK
and glyceroneogenesis. This is supported by results from Stark and colleagues (2014),
who found that silencing of mitochondrial PEPCK in the liver and kidneys resulted in a
43% decrease in circulating triglycerides. These findings are in contrast to those of
Hakimi et al. (2005) who found a 50% increase in circulating triglycerides in response to
whole body PEPCK ablation. The key difference in these findings is that one model
used whole body PEPCK ablation, while the other monitored tissue specific losses in
PEPCK. In adipose tissue, PEPCK plays a key role in triglyceride esterification and
storage via glyceroneogenesis. This tissue lacks glycerol kinase as an additional source
of glycerol-phosphate, and therefore, if whole body PEPCK is lost, adipose tissue has
lost the ability to esterify and store triglycerides, causing an increase in circulating
triglyceride levels. The liver, however, has sufficient glycerol kinase, and is therefore still
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able to make triglycerides in the absence of PEPCK, adding to the increased levels
found in circulation.
The current finding of decreased liver lipid is in contrast to Nash et al. (2013) who
demonstrated a significant increase in liver lipid percentage after the same treatment
dose and duration of DE-71. One striking difference between the current study and that
conducted by Nash et al. (2013) is the state of fasting of the rats. In the current study,
rats were fasted for 48 hours to sufficiently stress PEPCK and glyceroneogenesis,
whereas in the Nash et al. (2013) study, rats were fasted for only 16 hours. This 32-hour
difference in fasting time is significant and could explain key differences in findings in
liver lipid, as well as other metabolites such as serum glucose. Indeed, studies in mice
have indicated that serum glucose, lactate, and ammonia levels change significantly
between a 12-hour and a 48-hour fast, in addition to drastic increases in overall
carbohydrate and lipid metabolism (Sokolovic et al., 2008).
Histological data from the current study demonstrates lipid vacuolation in 7 of the
8 Penta-BDE treated rats, and none of the Controls. Although seemingly contradictory
to the decreased liver lipids, it was noted that vacuolation was only present midzonally.
PEPCK is mainly expressed in the periportal (Gebhardt, 1992) and pericentral regions
of the liver lobule (Sato et al., 2014). Because lipid vacuolation in response to PBDE
treatment is not occurring in an area of the liver lobule where PEPCK is highly
expressed, it may be that fat is reapportioned to the midzonal region, although the
reason for this is unclear. Despite midzonal lipid vacuolation seen in treated rats, it is
still feasible that total liver lipid is decreased.
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As discussed, the current data support that depressed hepatic
glyceroneogenesis and its associated consequences occur in response to suppression
of hepatic PEPCK activity. This is further accompanied by a decrease in hepatic PEPCK
protein. The mechanism by which PBDEs reduce PEPCK protein levels, the likely cause
of suppressed PEPCK activity, is unknown. It is well documented that PEPCK is
transcriptionally regulated in response to insulin, glucagon, and glucocorticoids through
a host of transcription factors (Chakravarty et al., 2005). Preliminary transcriptome
profiling of livers from treated rats however, indicates no change in PEPCK message in
response to PBDE treatment compared to control (unpublished data). Although these
data need to be verified using PEPCK-specific methodology, they suggest our finding of
PBDE-associated reductions in PEPCK protein levels may be due to post-translational
modifications that are induced by PBDEs and target PEPCK protein for degradation,
instead of decreased PEPCK gene transcription. This possibility is supported by
demonstrations of three potential mechanisms of post-translational modification of
PEPCK, including (1) acetylation (Jiang et al., 2011), (2) ADP-ribosylation (Diani-Moore
et al., 2013), and (3) nitration (Jaubert et al., 2012). All three mechanisms target
PEPCK for degradation, reducing protein levels. Furthermore, Diani-Moore and
colleagues (2013) demonstrated that PEPCK ADP-ribosylation can be a consequence
of 2,3,7,8-Tetrachlorodibenzodioxin (TCDD) exposure, so there is precedent for an
environmental chemical to initiate post-translational modification of PEPCK protein.
Nitration is linked to oxidative stress, a known consequence of PBDE exposure (Jaubert
et al., 2012, Albina et al., 2010), and is another possible mechanism of PBDE-
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associated decreased PEPCK protein. The role of these mechanisms in PBDE-induced
suppression of PEPCK protein have not yet been investigated.
In summary, the findings of this study demonstrate that chronic PBDE-exposure
disrupts hepatic lipid metabolism by decreasing glyceroneogenesis, increasing
circulating ketones, and decreasing hepatic and circulating triglycerides. In addition, this
suppression of hepatic glyceroneogenesis is associated with suppressed hepatic
PEPCK protein and activity. However, the effect of environmentally relevant doses of
PBDE on hepatic PEPCK and its associated metabolic pathways is still unknown.
Whether or not a decrease in hepatic glyceroneogenesis has health-associated
relevance, including disruption of insulin signaling via increased NEFA, remains to be
determined.
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TABLES AND FIGURES

Final Body
Weight (gms)

Liver Weight
(gms)

Liver Weight (%
Body Weight)

CON

268±51

10.5±0.31

3.9±0.11

TRT

283±62

13.9±0.31*

4.9±0.12*

Table 2. Body and Liver Weight
Final body weight, liver weight and liver as percent body weight for CON and TRT rats.
Two-way ANOVA indicated no effect of experiment time, thus the data has been
collapsed. There was, however a significant effect of DE-71 treatment. Data are
presented as mean ± SEM. 1n=14, 2n=13, *p<0.05 compared to CON.

BDE 47
(ng/g lipid)

BDE 99
(ng/g lipid)

BDE 100
(ng/g lipid)

CON

140.9±43.1

121.9±36.2

25.8±8.0

TRT

8349±888*

3750±487*

2069±217*

Table 3. Liver Burden of relevant PBDE congeners
Final concentrations of the 3 most abundant congeners (accounting for 97-99% of
hepatic PBDE burden) present in livers of CON and TRT rats (n=6, mean ± SEM).
*p<0.05 compared to CON.
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PEPCK	
  activity	
  (umol/min/g	
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  weight)	
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Figure 3. Hepatic PEPCK Activity
Kinetics curve for PEPCK activity in liver from CON (gray circles) and TRT rats (solid
black squares) (n=6, mean ± SEM). *p<0.05 compared to CON.

Vmax
(umol/min/g liver)

Km [malate]

CON

2.27±0.181

3.05±0.572

TRT

1.36±0.17*2

2.85±0.572

Table 4. Hepatic PEPCK enzyme kinetics
PEPCK Vmax and Km in liver from CON and TRT rats. (1n=5, 2n=6, mean ± SEM).
*p<0.05 compared to CON.
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Figure 4. Hepatic PEPCK Protein
Liver protein extracts from CON and TRT rats were separated by 10% SDS-PAGE and
PEPCK protein was analyzed by Western blotting. Rat liver extract (Santa Cruz
Biotechnology, Dallas, TX) was used as a positive control for hepatic PEPCK. A
representative blot comparing duplicate CON and TRT livers is presented (n=2 group).
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Glucose
(mg/dL)

Betahydroxybutarate
(mg/dL)

Triglycerides
(mg/dL)

NEFAs
(mEq/L)

Cholesterol
(mg/dL)

CON

177±19

21.8±1.4

83±1

0.682±0.052

78±6

TRT

92±5*

27.7±1.5*

61±7*

0.635±0.037

69±6

Table 5. Blood Metabolites
Serum metabolites for CON and TRT rats following 28 days treatment and subsequent
48-hour fast (n=8, mean ± SEM). *p<0.05 compared to CON.
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Figure 5. Hepatic Lipid Percentage
Lipid extracted from livers is presented as a percentage of total liver weight for both
CON (gray) and TRT (solid black) rats (n=6, mean ± SEM). *p<0.05 compared to CON.
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4A - Control

4B - Penta-BDE

Figure 6. Histological Examination of Hepatic Lipid Content
Representative photos of liver sections from CON and TRT rats evaluated by light
microscopy at 40x magnification. (4A) CON exhibited normal hepatic cellular
appearance. (4B) TRT had visible fatty vacuolation throughout the mid-zonal region that
was not found in liver tissue from CON rats. Black arrows indicate fat vacuoles.
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14-‐C	
  pyruvate	
  incorporation	
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lipids	
  (pmol/hr/mg	
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Figure 7. In Vitro Hepatic Glyceroneogenesis
Rates of glyceroneogenesis in liver explants from CON (gray) and TRT (solid) rats (n=6,
mean ± SEM). *p<0.05 compared to CON.
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APPENDICES

APPENDIX A
Transcriptome Data

Gene	
  	
  
Cyp2b1	
  
Cyp1a1	
  
LOC100909962	
  
Cyp2b2	
  
Cyp2c6v1	
  (NW_003806290	
  
1395..6073)	
  
Fabp4	
  
Ugt2b1	
  
Rnf13	
  (NW_003807001	
  
776757..811777)	
  
LOC100910385	
  
Ugt2b	
  
Dhtkd1	
  (NW_003812525	
  
173027..232220)	
  
Dhcr24	
  
C5	
  (NW_003807440	
  1439..23515)	
  
Rxra	
  
LOC100364457	
  
Rn18s	
  
Adipor2	
  
Abhd2	
  
Aldh1a1	
  
LOC257642	
  
Cpamd8	
  (NW_003808236	
  
6132..8613)	
  

	
  

Protein	
  
Cytochrome	
  P450,	
  family	
  2,	
  
subfamily	
  B,	
  polypeptide	
  1	
  
Cytochrome	
  P450,	
  family	
  1,	
  
subfamily	
  A,	
  polypeptide	
  1	
  
Cytochrome	
  P450	
  2B1-‐like	
  
Cytochrome	
  P450,	
  family	
  2,	
  
subfamily	
  B,	
  polypeptide	
  1	
  
Cytochrome	
  P450,	
  family	
  2,	
  
subfamily	
  C,	
  polypeptide	
  6,	
  variant	
  1	
  
Fatty	
  acid	
  binding	
  protein	
  4	
  
UDP	
  glucuronosyltransferase	
  2	
  
family,	
  polypeptide	
  B1	
  
Ring	
  finger	
  protein	
  13	
  
Peroxisomal	
  acyl-‐coenzyme	
  A	
  
oxidase	
  1-‐like	
  
UDP	
  glycosyltransferase	
  2	
  family,	
  
polypeptide	
  B	
  
Dehydrogenase	
  E1	
  and	
  transketolase	
  
domain	
  containing	
  1	
  
24-‐dehydrocholesterol	
  
reductase	
  
Complement	
  component	
  5	
  
Retinoid	
  x	
  receptor	
  alpha	
  
Ribosomal	
  protein	
  L9-‐like	
  
	
  
18s	
  ribosomal	
  RNA	
  
Adiponectin	
  receptor	
  2	
  
Abhydrolase	
  domain	
  containing	
  2	
  
Aldehyde	
  dehydrogenase	
  1	
  family,	
  
member	
  A1	
  
rRNA	
  promoter	
  binding	
  protein	
  
C3	
  and	
  PZP-‐like,	
  alpha-‐2-‐
macroglobulin	
  domain	
  containing	
  8	
  

Fold	
  change	
  (TRT	
  
vs.	
  CON	
  livers)	
  
1.80E+308	
  
553.26	
  
74.47	
  
44.86	
  
7.25	
  
6.86	
  
6.73	
  
6.43	
  
5.92	
  
5.43	
  
4.80	
  
4.75	
  
4.70	
  
4.57	
  
4.47	
  
3.91	
  
3.75	
  
3.71	
  
3.37	
  
3.23	
  
3.18	
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Cyp2c6v1	
  (NW_003806294	
  
23625..120993)	
  
Hnf4a	
  
Abcb11	
  (NW_003807561	
  
2064..90772)	
  
Mpeg1	
  
Afm	
  (NW_003811475	
  589..4764)	
  
Cyp1a2	
  
Ces2a	
  (NW_003812795	
  
59045..64825)	
  
Abcc2	
  
Lonp2	
  
Mup4	
  
Ephx1	
  
LOC100362027	
  
Acox1	
  

Cyp3a85-‐ps	
  
LOC100909666	
  
LOC100911718	
  
Slco1b3	
  
LOC100359498	
  
Hba-‐a2	
  
Hbb	
  
LOC360504	
  
LOC100134871	
  
Rpl30	
  
Hbb-‐b1	
  
Rps26	
  
LOC689064	
  
LOC100912411	
  
Rpl9	
  

Cytochrome	
  P450,	
  family	
  2,	
  
subfamily	
  C,	
  polypeptide	
  6,	
  variant	
  1	
  
Hepatocyte	
  nuclear	
  factor	
  4,	
  alpha	
  
ATP-‐binding	
  cassette,	
  subfamily	
  B	
  
(MDR/TAP),	
  member	
  11	
  
Macrophage	
  expressed	
  1	
  
Afamin	
  
Cytochrome	
  P450,	
  family	
  1,	
  
subfamily	
  A,	
  polypeptide	
  2	
  
Carboxylesterase	
  2A	
  
ATP-‐binding	
  cassette,	
  
subfamily	
  C	
  (CFTR/MRP),	
  member	
  2	
  
Ion	
  peptidase	
  2,	
  peroxisomal	
  
Major	
  urinalry	
  protein	
  4	
  
Epoxide	
  hydrolase	
  1,	
  microsomal	
  
(xenobiotic)	
  
Ribosomal	
  protein	
  L30-‐like	
  
Acyl-‐CoA	
  oxidase	
  1,	
  palmitoyl	
  
Cytochrome	
  P450,	
  family	
  3,	
  
subfamily	
  A,	
  polypeptide	
  85,	
  
pseudogene	
  
Complement	
  C4-‐like	
  
Cytochrome	
  p450	
  2C6-‐like	
  
Solute	
  carrier	
  organic	
  anion	
  
transporter	
  family,	
  member	
  1B3	
  
Ribosomal	
  protein	
  L35a-‐like	
  
Hemoglobin	
  alpha,	
  adult	
  chain	
  2	
  
Hemoglobin,	
  beta	
  
Hemoglobin,	
  alpha	
  2	
  
Beta	
  globin	
  minor	
  gene	
  
Ribosomal	
  protein	
  L30	
  
Hemoglobin,	
  beta	
  adult	
  major	
  chain	
  
Ribosomal	
  protein	
  S26	
  
Beta-‐globin	
  
Uncharacterized	
  
Ribosomal	
  protein	
  L9	
  

3.14	
  
2.88	
  
2.87	
  
2.85	
  
2.84	
  
2.78	
  
2.77	
  
2.67	
  
2.61	
  
2.55	
  
2.38	
  
2.35	
  
2.33	
  

2.19	
  
2.19	
  
2.14	
  
2.07	
  
-‐2.01	
  
-‐2.07	
  
-‐2.08	
  
-‐2.27	
  
-‐2.43	
  
-‐2.45	
  
-‐2.47	
  
-‐2.51	
  
-‐2.72	
  
-‐2.79	
  
-‐2.81	
  

To assess changes in gene expression of PEPCK, a library of mRNA expression was
created. Sixteen, male weanling Wistar rats were treated daily with 14 mg/kg body
weight DE-71 (TRT, n=8) or corn oil vehicle (CON, n=8) for 28 days. Rats were
euthanized after a 16 hr fast and livers were frozen. To reduce biological variability, 100
mg frozen tissue was dissected from 10 randomly selected livers from the CON (n=5)
and TRT (n=5) groups. The samples were then pooled within groups, resulting in 1500mg representative CON sample and 1-500mg representative TRT sample. Tissue
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could not be thawed at any time during the pooling process, so dissection of frozen
tissue was done quickly using a scalpel and tweezers in a walk-in refrigerator.
RNA was extracted from the CON and TRT samples using a commercially
available RiboPure kit (Ambion, Life Technologies). RNA samples were then sent to the
Hubbard Center for Genomic study at the University of New Hampshire for subsequent
mRNA extraction and gene sequencing. A library of genes expressed in the liver was
made using cDNA for both CON and TRT. Relative expression was quantified using an
Illumina HiSeq 2500 sequencer, and mapped to the reference genome of the Wistar rat.
Data are expressed as fold change in gene expression in TRT livers compared to CON.
There was no change in hepatic PEPCK-c or PEPCK-m in TRT livers compared to
CON. Genes that changed by 2-fold or greater in response to DE-71 are presented.
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APPENDIX B

Glyceroneogenesis Between-Animal Coefficient of Variation
Animal ID

P1
P2
P3
P4

Glyceroneogenesis
Rate
(pmol/hr/mg tissue)
13.57
14.96
13.39
16.54

Average
between
animals
14.61

Standard
Deviation

1.27

Coefficient
of
Variation
8.67%

To determine biological variation between animals for the glyceroneogenesis assay and
inform animal numbers necessary for subsequent experiments, four adult rats were
sacrificed and livers removed. Three-200 mg portions were taken from each liver and
used for glyceroneogenesis quantification. Each sample was run in duplicate.
Duplicates were averaged within each sample, and triplicates were then averaged within
each animal. The average and standard deviation between animals was used to
calculate the between-animal coefficient of variation.
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APPENDIX C

Glyceroneogenesis Within-Animal Coefficient of Variation
Sample ID

P5-1
P5-2
P5-3
P5-4
P5-5
P5-6
P5-7
P5-8
P5-9

Glyceroneogenesis
rate
(pmol/hr/mg tissue)
15.04
14.34
15.39
17.91
13.12
15.32
14.71
16.10
11.74

Average
within
animals

14.85

Standard
Deviation

1.64

Coefficient
of
Variation

11.09%

To determine biological variability within the liver for the glyceroneogenesis assay, one
adult rat was sacrificed and the liver was removed. Nine-200 mg portions were taken
from the liver and used for glyceroneogenesis quantification. Each sample was run in
duplicate. Duplicates were averaged within each sample, and then all nine samples
were averaged. The average and standard deviation was used to calculate the withinanimal coefficient of variation.
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APPENDIX D

PEPCK Activity in Subcutaneous Adipose Tissue

PEPCK	
  Activity	
  (nmol/min/mg	
  
protein)	
  

20	
  
18	
  
16	
  
14	
  
12	
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10	
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8	
  
6	
  
4	
  
2	
  
0	
  
Control	
  

Treatment	
  

To assess changes in PEPCK activity in adipose tissue, 16 male, weanling Wistar rats
were treated daily with 14 mg/kg bw DE-71 (TRT, n=8) or corn oil vehicle (CON, n=8) for
28 days. After a 16 hr fast, rats were euthanized and epididymal fat pads removed,
weighed, and placed in 10% saline solution for transport to the lab. Fat tissue was
homogenized and centrifuged at 23426 x g for cytosol isolation. PEPCK activity was
quantified as previously described (Nye et al., 2008). PEPCK activity in TRT adipose
tissue was suppressed by 17% compared to CON (p=0.068).
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APPENDIX E

Serum Metabolites
METABOLITE
Glucose (mg/dL)
Beta-hydroxybutarate (mg/dL)
Triglycerides (mg/dL)
NEFA (mEq/L)
Cholesterol (mg/dL)
Alanine Transaminase (U/L)
Alkaline Phosphatase (U/L)
Total Bilirubin (mg/dL)
Total Protein (g/dL)
Albumin (g/dL)
Urea Nitrogen (mg/dL)
Creatinine (mg/dL)
Calcium (mg/dL)
Sodium (mmol/L)
Potassium (mmol/L)
Chloride (mmol/L)
Globulin (g/dL)
Albumin/Globulin Ratio
Urea/Creatinine Ratio
Sodium/Potassium Ratio

CON
177 ± 19
21.8 ± 1.4
83 ± 1
0.682 ± 0.052
78 ± 6
24 ± 1
165 ± 11
.01 ± .04
6.6 ± .1
3.6 ± 0.1
15 ± 1
0.3 ± 0.01
12.6 ± 0.1
147 ± 1
7.9 ± 0.3
98 ± 1
3.0 ± 0.05
1.2 ± .03
52 ± 2
19 ± 1

TRT
95 ± 5*
27.7 ± 1.5*
61 ± 7*
0.635 ± 0.037
69 ± 6
27 ± 2
145 ± 9
.01 ± .04
6.5 ± 0.1
3.6 ± 0.1
13 ± 1
0.3 ± 0.02
12.2 ± 0.2
149 ± 0.5
7.6 ± 0.2
100 ± 1
2.9 ± 0.03
1.2 ± 0.03
50 ± 4
20 ± 1

To assess metabolic changes associated with PBDE exposure, 16 male, weanling
Wistar rats were treated daily with 14 mg/kg bw DE-71 (TRT, n=8) or corn oil vehicle
(CON, n=8) for 28 days. Rats were euthanized after a 48 hr fast and blood was
collected via cardiac puncture. Serum was separated and sent to Marshfield
Laboratories (Marshfield, WI) for metabolite quantification. A complete metabolic serum
profile of CON and TRT animals is presented; selected metabolites are listed in Table 5.
Data are presented as mean ± SE, *p<0.05.
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APPENDIX F

Hepatic PBDE Congeners
PBDE
Congener
BDE 100
BDE 99
BDE 47
BDE 28, 33
BDE 49
BDE 66
BDE 85, 155
Total

CON (ng/g lipid)
25.8 ± 8.0
121.9 ± 36.2
140.9 ± 43.1
1.1 ± 0.3
1.3 ± 0.4
1.4 ± 0.7
5.4 ± 1.9
297.5 ± 88.6

TRT (ng/g lipid)
2069 ± 217*
3750 ± 487*
8349 ± 888*
21.5 ± 2.8*
2.7 ± 0.4*
5.7 ± 0.3*
503.5 ± 49.8*
14701 ± 1603*

To determine hepatic PBDE burden in response to chronic high DE-71 treatment, 12
male, weanling Wistar rats were treated daily with 14 mg/kg bw DE-71 (TRT, n=6) or
corn oil vehicle (CON, n=6) for 28 days. After a 48 hr fast, rats were euthanized, and
livers were removed and frozen in 2 gram portions. Frozen livers were sent to Dr.
Heather Stapleton at Duke University for analysis of PBDE congeners. A complete
profile of BDE congeners measured in CON and TRT livers is presented. Data are
presented as mean±SE, *p<0.05.
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APPENDIX G

IACUC Approval Letter – Experiment 1
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APPENDIX H

IACUC Approval Letter – Experiment 2
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